



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

AUGUST 4, 2023

PTAS

NIKKI NOMURA
1 DNA WAY, MS-49
C/O GENENTECH, INC.
SOUTH SAN FRANCISCO, CA 94080

508047235

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 08/03/2023

REEL/FRAME: 064481/0565
NUMBER OF PAGES: 42

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: P37492-US/US-1/WO

ASSIGNOR:

LANDRY, MATTHEW LEO

DOC DATE: 10/05/2022

ASSIGNOR:

NILEWSKI, CHRISTIAN

DOC DATE: 10/04/2022

ASSIGNOR:

SIU, MICHAEL

DOC DATE: 10/04/2022

ASSIGNOR:

VILLEMURE, ELISIA

DOC DATE: 10/04/2022

ASSIGNOR:

WEI, BINQING

DOC DATE: 10/04/2022

ASSIGNOR:

DO, STEVEN

DOC DATE: 10/04/2022

ASSIGNOR:

GAZZARD, LEWIS JOHN

DOC DATE: 10/05/2022

ASSIGNOR:
GREEN, SAMANTHA ALYSON

DOC DATE: 10/04/2022

ASSIGNEE:
GENENTECH, INC.
1 DNA WAY
SOUTH SAN FRANCISCO, CALIFORNIA
94080-4990

APPLICATION NUMBER: 18199449 FILING DATE: 05/19/2023
PATENT NUMBER: ISSUE DATE:
TITLE: AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF

APPLICATION NUMBER: 63343959 FILING DATE: 05/19/2022
PATENT NUMBER: ISSUE DATE:
TITLE: AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF

APPLICATION NUMBER: FILING DATE: 05/19/2023
PATENT NUMBER: ISSUE DATE:
PCT NUMBER: US2023022914
TITLE: AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF

ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT8094389

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
MATTHEW LEO LANDRY	10/05/2022
CHRISTIAN NILEWSKI	10/04/2022
MICHAEL SIU	10/04/2022
ELISIA VILLEMURE	10/04/2022
BINQING WEI	10/04/2022
STEVEN DO	10/04/2022
LEWIS JOHN GAZZARD	10/05/2022
SAMANTHA ALYSON GREEN	10/04/2022
RECEIVING PARTY DATA	
Name:	GENENTECH, INC.
Street Address:	1 DNA WAY
City:	SOUTH SAN FRANCISCO
State/Country:	CALIFORNIA
Postal Code:	94080-4990
PROPERTY NUMBERS Total: 3	
Property Type	Number
Application Number:	63343959
Application Number:	18199449
PCT Number:	US2023022914
CORRESPONDENCE DATA	
Fax Number:	(650)952-9881
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	650-225-2497
Email:	nikkin@gene.com, global.patent_ops_filing@roche.com
Correspondent Name:	NIKKI NOMURA
Address Line 1:	1 DNA WAY, MS-49
Address Line 2:	C/O GENENTECH, INC.
Address Line 4:	SOUTH SAN FRANCISCO, CALIFORNIA 94080
ATTORNEY DOCKET NUMBER:	P37492-US/US-1/WO

CONFIRMATORY ASSIGNMENT

WHEREAS, **Matthew Leo LANDRY** ("**ASSIGNOR**"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "**INVENTION**"), for which application(s) has been filed as identified on **Exhibit A** (including any updated Exhibit A as provided herein); and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("**GENENTECH**"), is desirous of confirming its ownership interest in and to the INVENTION and in and to the applications and patents to be obtained therefor, or, if ASSIGNOR has not assigned his or her interest in the INVENTION to GENENTECH pursuant to a prior agreement with GENENTECH, acquiring an interest in and to the INVENTION, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), ASSIGNOR had assigned to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

To the extent that ASSIGNOR has not already assigned all of his or her rights, title and interest in the INVENTION to GENENTECH via a prior agreement with GENENTECH, then for good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR does hereby assign to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The ASSIGNOR agrees and authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR. ASSIGNOR agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of GENENTECH, its successors, assigns or delegates, and shall be binding upon the ASSIGNOR, his or her respective heirs, successors and assigns.

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of 5 October 2022, the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof:



Matthew Leo LANDRY

Mailing address:

1 DNA Way

South San Francisco, CA 94080

Citizenship: **US**


GENENTECH, INC.

Ian Griswold
Director and Assistant General Counsel
Genentech, Inc.
Authorized Corporate Signatory

IGS

EXHIBIT A TO CONFIRMATORY ASSIGNMENT*

Docket No.	Title	Serial Number	Filing Date
P37492-US	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	63/343959	19 May 2022

*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date
P37492-US	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	63/343959	19 May 2022
P37492-AR	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	P230101266	19 May 2023
P37492-TW	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	112118800	19 May 2023
P37492-US-1	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	18/199449	19 May 2023
P37492-WO	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	PCT/US2023/022914	19 May 2023

CONFIRMATORY ASSIGNMENT

WHEREAS, **Christian NILEWSKI** ("**ASSIGNOR**"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "**INVENTION**"), for which application(s) has been filed as identified on **Exhibit A** (including any updated Exhibit A as provided herein); and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("**GENENTECH**"), is desirous of confirming its ownership interest in and to the INVENTION and in and to the applications and patents to be obtained therefor, or, if ASSIGNOR has not assigned his or her interest in the INVENTION to GENENTECH pursuant to a prior agreement with GENENTECH, acquiring an interest in and to the INVENTION, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), ASSIGNOR had assigned to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

To the extent that ASSIGNOR has not already assigned all of his or her rights, title and interest in the INVENTION to GENENTECH via a prior agreement with GENENTECH, then for good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR does hereby assign to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The ASSIGNOR agrees and authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR. ASSIGNOR agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of GENENTECH, its successors, assigns or delegates, and shall be binding upon the ASSIGNOR, his or her respective heirs, successors and assigns.

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of 4 October 2022, the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof:



Christian NILEWSKI

Mailing address:

1 DNA Way

South San Francisco, CA 94080

Citizenship: **Germany (DE)**



GENENTECH, INC.



Ian Griswold
Director and Assistant General Counsel
Genentech, Inc.
Authorized Corporate Signatory

EXHIBIT A TO CONFIRMATORY ASSIGNMENT*

Docket No.	Title	Serial Number	Filing Date
P37492-US	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	63/343959	19 May 2022

*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date
P37492-US	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	63/343959	19 May 2022
P37492-AR	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	P230101266	19 May 2023
P37492-TW	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	112118800	19 May 2023
P37492-US-1	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	18/199449	19 May 2023
P37492-WO	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	PCT/US2023/022914	19 May 2023

CONFIRMATORY ASSIGNMENT

WHEREAS, Michael SIU ("ASSIGNOR"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "INVENTION"), for which application(s) has been filed as identified on **Exhibit A** (including any updated Exhibit A as provided herein); and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("GENENTECH"), is desirous of confirming its ownership interest in and to the INVENTION and in and to the applications and patents to be obtained therefor, or, if ASSIGNOR has not assigned his or her interest in the INVENTION to GENENTECH pursuant to a prior agreement with GENENTECH, acquiring an interest in and to the INVENTION, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), ASSIGNOR had assigned to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.


To the extent that ASSIGNOR has not already assigned all of his or her rights, title and interest in the INVENTION to GENENTECH via a prior agreement with GENENTECH, then for good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR does hereby assign to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The ASSIGNOR agrees and authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR. ASSIGNOR agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of GENENTECH, its successors, assigns or delegates, and shall be binding upon the ASSIGNOR, his or her respective heirs, successors and assigns.

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of 4 October 2022, the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof:




Michael SIU

Mailing address:

1 DNA Way

South San Francisco, CA 94080

Citizenship: **US**



GENENTECH, INC.


John Griswold
Director and Assistant General Counsel
Genentech, Inc.
Authorized Corporate Signatory

EXHIBIT A TO CONFIRMATORY ASSIGNMENT*

Docket No.	Title	Serial Number	Filing Date
P37492-US	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	63/343959	19 May 2022

*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date
P37492-US	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	63/343959	19 May 2022
P37492-AR	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	P230101266	19 May 2023
P37492-TW	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	112118800	19 May 2023
P37492-US-1	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	18/199449	19 May 2023
P37492-WO	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	PCT/US2023/022914	19 May 2023

CONFIRMATORY ASSIGNMENT

WHEREAS, Elisia VILLEMURE ("**ASSIGNOR**"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "**INVENTION**"), for which application(s) has been filed as identified on **Exhibit A** (including any updated Exhibit A as provided herein); and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("**GENENTECH**"), is desirous of confirming its ownership interest in and to the INVENTION and in and to the applications and patents to be obtained therefor, or, if ASSIGNOR has not assigned his or her interest in the INVENTION to GENENTECH pursuant to a prior agreement with GENENTECH, acquiring an interest in and to the INVENTION, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), ASSIGNOR had assigned to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.


To the extent that ASSIGNOR has not already assigned all of his or her rights, title and interest in the INVENTION to GENENTECH via a prior agreement with GENENTECH, then for good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR does hereby assign to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The ASSIGNOR agrees and authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR. ASSIGNOR agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of GENENTECH, its successors, assigns or delegates, and shall be binding upon the ASSIGNOR, his or her respective heirs, successors and assigns.

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of 4 October 2022, the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof:




Elisia VILLEMURE

Mailing address:

1 DNA Way

South San Francisco, CA 94080

Citizenship: **Canada (CA)**



GENENTECH, INC.

Ian Griswold
Director and Assistant General Counsel
Genentech, Inc.
Authorized Corporate Signatory

Res AS

EXHIBIT A TO CONFIRMATORY ASSIGNMENT*

Docket No.	Title	Serial Number	Filing Date
P37492-US	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	63/343959	19 May 2022

*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date
P37492-US	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	63/343959	19 May 2022
P37492-AR	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	P230101266	19 May 2023
P37492-TW	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	112118800	19 May 2023
P37492-US-1	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	18/199449	19 May 2023
P37492-WO	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	PCT/US2023/022914	19 May 2023

CONFIRMATORY ASSIGNMENT

WHEREAS, **BinQing WEI** ("**ASSIGNOR**"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "**INVENTION**"), for which application(s) has been filed as identified on **Exhibit A** (including any updated Exhibit A as provided herein); and

WHEREAS, **GENENTECH, INC.**, a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("**GENENTECH**"), is desirous of confirming its ownership interest in and to the **INVENTION** and in and to the applications and patents to be obtained therefor, or, if **ASSIGNOR** has not assigned his or her interest in the **INVENTION** to **GENENTECH** pursuant to a prior agreement with **GENENTECH**, acquiring an interest in and to the **INVENTION**, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, **ASSIGNOR** confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), **ASSIGNOR** had assigned to **GENENTECH**, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the **INVENTION**, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

To the extent that **ASSIGNOR** has not already assigned all of his or her rights, title and interest in the **INVENTION** to **GENENTECH** via a prior agreement with **GENENTECH**, then for good and valuable consideration the receipt of which is hereby acknowledged, **ASSIGNOR** does hereby assign to **GENENTECH**, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the **INVENTION**, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The **ASSIGNOR** agrees and authorizes **GENENTECH**, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by **GENENTECH**, its successors, assigns and delegates in and to the **INVENTION** when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by **ASSIGNOR**. **ASSIGNOR** agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of **GENENTECH**, its successors, assigns or delegates, and shall be binding upon the **ASSIGNOR**, his or her respective heirs, successors and assigns.

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of 4 October 2022, the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof:

BinQing Wei

BinQing WEI

Mailing address:

1 DNA Way

South San Francisco, CA 94080

Citizenship: **US**

Ian Griswold

GENENTECH, INC.

Ian Griswold
Director and Assistant General Counsel
Genentech, Inc.
Authorized Corporate Signatory

Boas

EXHIBIT A TO CONFIRMATORY ASSIGNMENT*

Docket No.	Title	Serial Number	Filing Date
P37492-US	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	63/343959	19 May 2022

*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date
P37492-US	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	63/343959	19 May 2022
P37492-AR	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	P230101266	19 May 2023
P37492-TW	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	112118800	19 May 2023
P37492-US-1	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	18/199449	19 May 2023
P37492-WO	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	PCT/US2023/022914	19 May 2023

CONFIRMATORY ASSIGNMENT

WHEREAS, **Steven DO** ("**ASSIGNOR**"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "**INVENTION**"), for which application(s) has been filed as identified on **Exhibit A** (including any updated Exhibit A as provided herein); and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("**GENENTECH**"), is desirous of confirming its ownership interest in and to the INVENTION and in and to the applications and patents to be obtained therefor, or, if ASSIGNOR has not assigned his or her interest in the INVENTION to GENENTECH pursuant to a prior agreement with GENENTECH, acquiring an interest in and to the INVENTION, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), ASSIGNOR had assigned to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

To the extent that ASSIGNOR has not already assigned all of his or her rights, title and interest in the INVENTION to GENENTECH via a prior agreement with GENENTECH, then for good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR does hereby assign to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The ASSIGNOR agrees and authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR. ASSIGNOR agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of GENENTECH, its successors, assigns or delegates, and shall be binding upon the ASSIGNOR, his or her respective heirs, successors and assigns.

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of 4 October 2022, the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof:




Steven DO

Mailing address:

1 DNA Way

South San Francisco, CA 94080

Citizenship: **US**



GENENTECH, INC.



Ian Griswold
Director and Assistant General Counsel
Genentech, Inc.
Authorized Corporate Signatory

EXHIBIT A TO CONFIRMATORY ASSIGNMENT*

Docket No.	Title	Serial Number	Filing Date
P37492-US	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	63/343959	19 May 2022

*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date
P37492-US	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	63/343959	19 May 2022
P37492-AR	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	P230101266	19 May 2023
P37492-TW	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	112118800	19 May 2023
P37492-US-1	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	18/199449	19 May 2023
P37492-WO	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	PCT/US2023/022914	19 May 2023

CONFIRMATORY ASSIGNMENT

WHEREAS, Lewis John GAZZARD ("ASSIGNOR"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "INVENTION"), for which application(s) has been filed as identified on **Exhibit A** (including any updated Exhibit A as provided herein); and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("GENENTECH"), is desirous of confirming its ownership interest in and to the INVENTION and in and to the applications and patents to be obtained therefor, or, if ASSIGNOR has not assigned his or her interest in the INVENTION to GENENTECH pursuant to a prior agreement with GENENTECH, acquiring an interest in and to the INVENTION, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), ASSIGNOR had assigned to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

To the extent that ASSIGNOR has not already assigned all of his or her rights, title and interest in the INVENTION to GENENTECH via a prior agreement with GENENTECH, then for good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR does hereby assign to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The ASSIGNOR agrees and authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR. ASSIGNOR agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of GENENTECH, its successors, assigns or delegates, and shall be binding upon the ASSIGNOR, his or her respective heirs, successors and assigns.

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of 5 October 2022, the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof:



Lewis John GAZZARD

Mailing address:

1 DNA Way

South San Francisco, CA 94080

Citizenship: **Great Britain (GB)**



GENENTECH, INC.

Ian Griswold
Director and Assistant General Counsel
Genentech, Inc.
Authorized Corporate Signatory

EXHIBIT A TO CONFIRMATORY ASSIGNMENT*

Docket No.	Title	Serial Number	Filing Date
P37492-US	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	63/343959	19 May 2022

*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date
P37492-US	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	63/343959	19 May 2022
P37492-AR	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	P230101266	19 May 2023
P37492-TW	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	112118800	19 May 2023
P37492-US-1	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	18/199449	19 May 2023
P37492-WO	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	PCT/US2023/022914	19 May 2023

CONFIRMATORY ASSIGNMENT

WHEREAS, **Samantha Alyson GREEN** ("**ASSIGNOR**"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "**INVENTION**"), for which application(s) has been filed as identified on **Exhibit A** (including any updated Exhibit A as provided herein); and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("**GENENTECH**"), is desirous of confirming its ownership interest in and to the INVENTION and in and to the applications and patents to be obtained therefor, or, if ASSIGNOR has not assigned his or her interest in the INVENTION to GENENTECH pursuant to a prior agreement with GENENTECH, acquiring an interest in and to the INVENTION, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), ASSIGNOR had assigned to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

To the extent that ASSIGNOR has not already assigned all of his or her rights, title and interest in the INVENTION to GENENTECH via a prior agreement with GENENTECH, then for good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR does hereby assign to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The ASSIGNOR agrees and authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR. ASSIGNOR agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of GENENTECH, its successors, assigns or delegates, and shall be binding upon the ASSIGNOR, his or her respective heirs, successors and assigns.

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of 4 October 2022, the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof:



Samantha Alyson GREEN

Mailing address:

1 DNA Way

South San Francisco, CA 94080

Citizenship: **US**



GENENTECH, INC.

Ian Griswold
Director and Assistant General Counsel
Genentech, Inc.
Authorized Corporate Signatory



EXHIBIT A TO CONFIRMATORY ASSIGNMENT*

Docket No.	Title	Serial Number	Filing Date
P37492-US	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	63/343959	19 May 2022

*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date
P37492-US	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	63/343959	19 May 2022
P37492-AR	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	P230101266	19 May 2023
P37492-TW	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	112118800	19 May 2023
P37492-US-1	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	18/199449	19 May 2023
P37492-WO	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	PCT/US2023/022914	19 May 2023



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

AUGUST 4, 2023

PTAS

NIKKI NOMURA
1 DNA WAY, MS-49
C/O GENENTECH, INC.
SOUTH SAN FRANCISCO, CA 94080

508047243

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 08/03/2023

REEL/FRAME: 064481/0538
NUMBER OF PAGES: 10

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: P37492-US-1 AND P37492-W0

ASSIGNOR:
WANG, YONG

DOC DATE: 06/20/2023

ASSIGNOR:
ASHLEY, MELISSA ANN

DOC DATE: 07/17/2023

ASSIGNEE:
GENENTECH, INC.
1 DNA WAY
SOUTH SAN FRANCISCO, CALIFORNIA
94080-4990

APPLICATION NUMBER: 18199449

FILING DATE: 05/19/2023

PATENT NUMBER:

ISSUE DATE:

TITLE: AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF

APPLICATION NUMBER:

FILING DATE: 05/19/2023

PATENT NUMBER:

ISSUE DATE:

PCT NUMBER: US2023022914

TITLE: AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF

ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT8094397

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
YONG WANG	06/20/2023
MELISSA ANN ASHLEY	07/17/2023
RECEIVING PARTY DATA	
Name:	GENENTECH, INC.
Street Address:	1 DNA WAY
City:	SOUTH SAN FRANCISCO
State/Country:	CALIFORNIA
Postal Code:	94080-4990
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	18199449
PCT Number:	US2023022914
CORRESPONDENCE DATA	
Fax Number:	(650)952-9881
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	650-225-2497
Email:	nikkin@gene.com
Correspondent Name:	NIKKI NOMURA
Address Line 1:	1 DNA WAY, MS-49
Address Line 2:	C/O GENENTECH, INC.
Address Line 4:	SOUTH SAN FRANCISCO, CALIFORNIA 94080
ATTORNEY DOCKET NUMBER:	P37492-US-1 AND P37492-WO
NAME OF SUBMITTER:	NIKKI NOMURA
SIGNATURE:	/Nikki NOMURA/
DATE SIGNED:	08/03/2023
Total Attachments: 8	
source=P37492 - Executed Assignment I-As from GNE inventors to GNE (added inventors)#page1.tif	
source=P37492 - Executed Assignment I-As from GNE inventors to GNE (added inventors)#page2.tif	
source=P37492 - Executed Assignment I-As from GNE inventors to GNE (added inventors)#page3.tif	

CONFIRMATORY ASSIGNMENT

WHEREAS, **Yong WANG** ("**ASSIGNOR**"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "**INVENTION**"), for which application(s) has been filed as identified on **Exhibit A** (including any updated Exhibit A as provided herein); and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("**GENENTECH**"), is desirous of confirming its ownership interest in and to the INVENTION and in and to the applications and patents to be obtained therefor, or, if ASSIGNOR has not assigned his or her interest in the INVENTION to GENENTECH pursuant to a prior agreement with GENENTECH, acquiring an interest in and to the INVENTION, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), ASSIGNOR had assigned to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

To the extent that ASSIGNOR has not already assigned all of his or her rights, title and interest in the INVENTION to GENENTECH via a prior agreement with GENENTECH, then for good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR does hereby assign to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The ASSIGNOR agrees and authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR. ASSIGNOR agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of GENENTECH, its successors, assigns or delegates, and shall be binding upon the ASSIGNOR, his or her respective heirs, successors and assigns.

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of 20 June 2023, the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof:




Yong WANG

Mailing address:

1 DNA Way

South San Francisco, CA 94080

Citizenship: **CN**



GENENTECH, INC.

IGS

Ian Griswold
Director and Assistant General Counsel
Genentech, Inc.
Authorized Corporate Signatory

EXHIBIT A TO CONFIRMATORY ASSIGNMENT*

Docket No.	Title	Serial Number	Filing Date
P37492-AR	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	P230101266	19 May 2023
P37492-TW	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	112118800	19 May 2023
P37492-US-1	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	18/199449	19 May 2023
P37492-WO	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	PCT/US2023/022914	19 May 2023

*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date

CONFIRMATORY ASSIGNMENT

WHEREAS, **Melissa Ann ASHLEY** ("**ASSIGNOR**"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "**INVENTION**"), for which application(s) has been filed as identified on **Exhibit A** (including any updated Exhibit A as provided herein); and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("**GENENTECH**"), is desirous of confirming its ownership interest in and to the INVENTION and in and to the applications and patents to be obtained therefor, or, if ASSIGNOR has not assigned his or her interest in the INVENTION to GENENTECH pursuant to a prior agreement with GENENTECH, acquiring an interest in and to the INVENTION, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), ASSIGNOR had assigned to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

To the extent that ASSIGNOR has not already assigned all of his or her rights, title and interest in the INVENTION to GENENTECH via a prior agreement with GENENTECH, then for good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR does hereby assign to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The ASSIGNOR agrees and authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR. ASSIGNOR agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of GENENTECH, its successors, assigns or delegates, and shall be binding upon the ASSIGNOR, his or her respective heirs, successors and assigns.

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of 17 July 2023, the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof:


Melissa Ann ASHLEY
Mailing address:
1 DNA Way
South San Francisco, CA 94080
Citizenship: **US**


GENENTECH, INC.

Ian Griswold
Director and Assistant General Counsel
Genentech, Inc.
Authorized Corporate Signatory

EXHIBIT A TO CONFIRMATORY ASSIGNMENT*

Docket No.	Title	Serial Number	Filing Date
P37492-AR	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	P230101266	19 May 2023
P37492-TW	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	112118800	19 May 2023
P37492-US-1	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	18/199449	19 May 2023
P37492-WO	AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF	PCT/US2023/022914	19 May 2023

*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date